Neuroimaging outcomes associated with mild cognitive impairment subtypes in Parkinson's disease: A systematic review.

Cognitive dysfunction Electroencephalography Executive function Magnetic resonance imaging Memory Positron-emission tomography Single photon emission computed tomography

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
02 2022
Historique:
received: 06 12 2021
revised: 26 01 2022
accepted: 11 02 2022
pubmed: 8 3 2022
medline: 30 4 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Mild cognitive impairment in Parkinson's disease (PD-MCI) is heterogenous and cognitive subtypes have been identified. However, the anatomo-functional bases of each subtype remain partly unknown. To propose a description of the current literature on neuroimaging findings associated with cognitive subtypes of PD-MCI. PubMed/Medline, Embase, PsycINFO and the Cochrane Library databases were searched (until April 2021). Studies comparing PD-MCI cognitive subtypes with healthy controls (HC) and PD patients with normal cognition (PD-NC) on any neuroimaging outcome were included. Ten studies met the inclusion criteria. Six used structural MRI methods, two functional MRI methods, one electroencephalography and five positron or single-photon emission tomography. Most studies (n = 8) determined PD-MCI subtypes based on memory impairment and two based on executive impairment. Compared with HC and/or PD-NC, brain modifications were found in PD patients (a) with amnestic MCI and, to a lesser extent, non-amnestic MCI in occipital, parietal and temporal regions, (b) with executive MCI in frontal and striatal regions and (c) with non-executive MCI in posterior cortical regions. Very few neuroimaging studies have considered cognitive heterogeneity that exists within PD-MCI, making it difficult to draw robust conclusions regarding brain modifications associated with specific subtypes. Given the promising potential of neuroimaging methods in both clinical practice and research, further studies are needed to overcome the limitations of the current literature.

Sections du résumé

BACKGROUND
Mild cognitive impairment in Parkinson's disease (PD-MCI) is heterogenous and cognitive subtypes have been identified. However, the anatomo-functional bases of each subtype remain partly unknown.
OBJECTIVE
To propose a description of the current literature on neuroimaging findings associated with cognitive subtypes of PD-MCI.
METHODS
PubMed/Medline, Embase, PsycINFO and the Cochrane Library databases were searched (until April 2021). Studies comparing PD-MCI cognitive subtypes with healthy controls (HC) and PD patients with normal cognition (PD-NC) on any neuroimaging outcome were included.
RESULTS
Ten studies met the inclusion criteria. Six used structural MRI methods, two functional MRI methods, one electroencephalography and five positron or single-photon emission tomography. Most studies (n = 8) determined PD-MCI subtypes based on memory impairment and two based on executive impairment. Compared with HC and/or PD-NC, brain modifications were found in PD patients (a) with amnestic MCI and, to a lesser extent, non-amnestic MCI in occipital, parietal and temporal regions, (b) with executive MCI in frontal and striatal regions and (c) with non-executive MCI in posterior cortical regions.
CONCLUSIONS
Very few neuroimaging studies have considered cognitive heterogeneity that exists within PD-MCI, making it difficult to draw robust conclusions regarding brain modifications associated with specific subtypes. Given the promising potential of neuroimaging methods in both clinical practice and research, further studies are needed to overcome the limitations of the current literature.

Identifiants

pubmed: 35249807
pii: S1353-8020(22)00039-6
doi: 10.1016/j.parkreldis.2022.02.006
pii:
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-137

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Quentin Devignes (Q)

Univ. Lille, Inserm, CHU Lille, Lille Neurosciences and Cognition, F-59000, Lille, France. Electronic address: qdevignes@gmail.com.

Renaud Lopes (R)

Univ. Lille, Inserm, CHU Lille, Lille Neurosciences and Cognition, F-59000, Lille, France; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, F-59000, Lille, France.

Kathy Dujardin (K)

Univ. Lille, Inserm, CHU Lille, Lille Neurosciences and Cognition, F-59000, Lille, France; Neurology and Movement Disorders Department, Lille University Medical Centre, F-59000, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH